Shares of Avanos Medical Inc (NYSE:AVNS) have earned an average recommendation of “Hold” from the seven research firms that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $63.50.

A number of research firms have recently commented on AVNS. KeyCorp reduced their price target on shares of Avanos Medical from $68.00 to $67.00 and set an “overweight” rating for the company in a research report on Tuesday, December 18th. Zacks Investment Research upgraded shares of Avanos Medical from a “sell” rating to a “hold” rating in a research report on Monday, March 25th. ValuEngine lowered shares of Avanos Medical from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Finally, Barclays lowered shares of Avanos Medical from an “equal weight” rating to an “underweight” rating in a research report on Friday, January 4th.

A number of large investors have recently made changes to their positions in the stock. BlackRock Inc. grew its position in Avanos Medical by 3.4% in the fourth quarter. BlackRock Inc. now owns 5,441,296 shares of the company’s stock worth $243,716,000 after acquiring an additional 177,524 shares in the last quarter. Vanguard Group Inc. purchased a new position in Avanos Medical in the third quarter worth $294,519,000. Vanguard Group Inc purchased a new position in Avanos Medical in the third quarter worth $294,519,000. Victory Capital Management Inc. grew its position in Avanos Medical by 79.4% in the fourth quarter. Victory Capital Management Inc. now owns 1,673,175 shares of the company’s stock worth $74,942,000 after acquiring an additional 740,450 shares in the last quarter. Finally, Paradice Investment Management LLC grew its position in Avanos Medical by 119.5% in the fourth quarter. Paradice Investment Management LLC now owns 1,492,595 shares of the company’s stock worth $66,853,000 after acquiring an additional 812,659 shares in the last quarter. Institutional investors own 92.70% of the company’s stock.

AVNS stock traded up $0.87 during midday trading on Monday, reaching $45.01. 272,800 shares of the company’s stock traded hands, compared to its average volume of 341,731. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.70 and a quick ratio of 2.24. Avanos Medical has a 52 week low of $38.00 and a 52 week high of $72.96. The stock has a market capitalization of $2.09 billion, a price-to-earnings ratio of 54.89 and a beta of 1.44.

Avanos Medical (NYSE:AVNS) last issued its earnings results on Tuesday, February 26th. The company reported $0.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.09. The business had revenue of $169.90 million for the quarter, compared to analysts’ expectations of $166.88 million. Avanos Medical had a net margin of 8.81% and a return on equity of 7.20%. The business’s revenue for the quarter was up 2.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.73 EPS. Equities research analysts anticipate that Avanos Medical will post 1.25 EPS for the current year.

About Avanos Medical

Avanos Medical, Inc operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes.

Read More: Green Investing

Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.